At the Annual General Meeting of AUXESIS PHARMA HOLDING AB (publ), held on June 12, 2026, shareholders resolved to elect three new members to the Board of Directors. Roar Adelsten was elected Chairman of the Board, while Anna Tenstam and Lars-Olof Peterson were elected Board Members.
The appointments strengthen the Board’s combined expertise and experience ahead of the Company’s continued development and strategic work. The newly elected members bring valuable experience in business development, leadership, strategy and corporate development, which is expected to strengthen AUXESIS PHARMA HOLDING AB’s ability to achieve its long-term objectives.
– We look forward to contributing together to the Company’s continued development and to creating long-term value for shareholders, partners and other stakeholders. AUXESIS PHARMA HOLDING operates in an area with significant opportunities, and we look forward to supporting the Company’s next phase of development, says newly elected Chairman of the Board Roar Adelsten.
The Annual General Meeting also resolved to adopt the income statement and balance sheet and to discharge the Board of Directors and the Chief Executive Officer from liability for the previous financial year.
The new Board assumes office immediately following the conclusion of the Annual General Meeting.
For further information
AUXESIS PHARMA HOLDING AB (publ)
Email: auxesis@auxesispharma.com
Phone: +46 (0)8 771 43 00
About AUXESIS PHARMA HOLDING AB (publ)
AUXESIS PHARMA HOLDING AB (publ) is a Swedish life science company focused on developing and commercializing innovative medicines that contribute to improved health and quality of life.